Currently Enrolling for:

A Long Term Study to Find Out if Macitentan is an Effective and Safe Treatment for Patients With Heart Failure With Preserved Ejection Fraction and Pulmonary Vascular Disease (SERENADE OL)

The primary objective of this open-label (OL) extension trial is to study the long-term safety and efficacy of macitentan in subjects with heart failure with preserved ejection fraction (HFpEF) and pulmonary vascular disease (PVD) beyond the 52 weeks of treatment in the double-blind parent SERENADE study (AC-055G202, NCT03153111). Furthermore, this OL extension study will give eligible subjects who have completed the main study (SERENADE/AC-055G202, NCT03153111) an opportunity to continue or start receiving macitentan.

 

Eligibility Criteria:

Sex/Gender	Sexes Eligible for Study: All

Ages	18 Years and older   (Adult, Older Adult)

Accepts Healthy Volunteers	No

Qualified participants may receive:
	Study-related medication at no cost
	Study-related medical exams at no cost
No insurance is needed to participate.

If you are interested in participating in our study, please fill out the form below or call us at (919) 267-5209.

  
Enroll Now: